2. Academic Validation
  3. A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation

A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation

  • Am J Hum Genet. 2018 Oct 4;103(4):553-567. doi: 10.1016/j.ajhg.2018.09.003.
Carlos R Ferreira 1,  Zhi-Jie Xia 2,  Aurélie Clément 3,  David A Parry 4,  Mariska Davids 5,  Fulya Taylan 6,  Prashant Sharma 5,  Coleman T Turgeon 7,  Bernardo Blanco-Sánchez 3,  Bobby G Ng 2,  Clare V Logan 4,  Lynne A Wolfe 5,  Benjamin D Solomon 8,  Megan T Cho 8,  Ganka Douglas 8,  Daniel R Carvalho 9,  Heiko Bratke 10,  Marte Gjøl Haug 11,  Jennifer B Phillips 3,  Jeremy Wegner 3,  Michael Tiemeyer 12,  Kazuhiro Aoki 12,  Undiagnosed Diseases Network,  Scottish Genome Partnership,  Ann Nordgren 13,  Anna Hammarsjö 13,  Angela L Duker 14,  Luis Rohena 15,  Hanne Buciek Hove 16,  Jakob Ek 17,  David Adams 5,  Cynthia J Tifft 5,  Tito Onyekweli 5,  Tara Weixel 5,  Ellen Macnamara 5,  Kelly Radtke 18,  Zöe Powis 18,  Dawn Earl 19,  Melissa Gabriel 20,  Alvaro H Serrano Russi 20,  Lauren Brick 21,  Mariya Kozenko 21,  Emma Tham 13,  Kimiyo M Raymond 7,  John A Phillips 3rd 22,  George E Tiller 23,  William G Wilson 24,  Rizwan Hamid 22,  May C V Malicdan 5,  Gen Nishimura 25,  Giedre Grigelioniene 13,  Andrew Jackson 4,  Monte Westerfield 3,  Michael B Bober 14,  William A Gahl 5,  Hudson H Freeze 2
Affiliations

Affiliations

  • 1 Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA; Division of Genetics and Metabolism, Children's National Health System, Washington, DC 20010, USA. Electronic address: carlos.ferreira@nih.gov.
  • 2 Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
  • 3 Institute of Neuroscience, University of Oregon, Eugene, OR 97403, USA.
  • 4 MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
  • 5 Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • 6 Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden.
  • 7 Biochemical Genetics Laboratory, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
  • 8 GeneDx, Gaithersburg, MD 20877, USA.
  • 9 Genetic Unit, SARAH Network of Rehabilitation Hospitals, Brasília-DF, 70335-901, Brazil.
  • 10 Department of Internal Medicine, Section of Paediatrics, Haugesund District Hospital, Fonna Health Trust, 5527 Haugesund, Norway.
  • 11 Department of Medical Genetics, St. Olav's Hospital, 7006 Trondheim, Norway.
  • 12 Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA.
  • 13 Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden; Department of Clinical Genetics, Karolinska University Hospital, 17176 Stockholm, Sweden.
  • 14 Division of Orthogenetics, A.I. duPont Hospital for Children, Wilmington, DE, 19803, USA.
  • 15 Division of Genetics, Department of Pediatrics, San Antonio Military Medical Center, San Antonio, TX, 78234, USA; Department of Pediatrics, University of Texas Health Science Center, San Antonio, TX, 78229, USA.
  • 16 Section of Rare Disorders, Department of Pediatrics, Rigshospitalet, 2100 Copenhagen, Denmark.
  • 17 Department of Clinical Genetics, Rigshospitalet, 2100 Copenhagen, Denmark.
  • 18 Ambry Genetics, Aliso Viejo, CA 92656, USA.
  • 19 Division of Genetic Medicine, Seattle Children's, Seattle, WA, 98105, USA.
  • 20 Division of Medical Genetics, Children's Hospital of Los Angeles, University of Southern California, Los Angeles, CA 90027, USA.
  • 21 Division of Genetics, Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton Ontario L8S 4J9, Canada.
  • 22 Division of Medical genetics and Genomic Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
  • 23 Department of Genetics, Kaiser Permanente, Los Angeles, CA 90027, USA.
  • 24 Department of Pediatrics, University of Virginia Health System, Charlottesville, VA 20903, USA.
  • 25 Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo 108-8639, Japan; Center for Intractable Diseases, Saitama Medical University Hospital, Saitama 350-0495, Japan.
PMID: 30290151 DOI: 10.1016/j.ajhg.2018.09.003
Abstract

The conserved oligomeric Golgi (COG) complex is involved in intracellular vesicular transport, and is composed of eight subunits distributed in two lobes, lobe A (COG1-4) and lobe B (COG5-8). We describe fourteen individuals with Saul-Wilson syndrome, a rare form of primordial dwarfism with characteristic facial and radiographic features. All affected subjects harbored heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid substitution (p.Gly516Arg). Affected individuals' fibroblasts, whose COG4 mRNA and protein were not decreased, exhibited delayed anterograde vesicular trafficking from the ER to the Golgi and accelerated retrograde vesicular recycling from the Golgi to the ER. This altered steady-state equilibrium led to a decrease in Golgi volume, as well as morphologic abnormalities with collapse of the Golgi stacks. Despite these abnormalities of the Golgi apparatus, protein glycosylation in sera and fibroblasts from affected subjects was not notably altered, but decorin, a proteoglycan secreted into the extracellular matrix, showed altered Golgi-dependent glycosylation. In summary, we define a specific heterozygous COG4 substitution as the molecular basis of Saul-Wilson syndrome, a rare skeletal dysplasia distinct from biallelic COG4-CDG.

Figures